Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2005-06-17
2011-11-22
Arnold, Ernst (Department: 1613)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C514S001100, C514S010300, C514S722000, C514S899000
Reexamination Certificate
active
08062652
ABSTRACT:
The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).
REFERENCES:
patent: 2513014 (1950-06-01), Fields
patent: 3921632 (1975-11-01), Bardani
patent: 4285987 (1981-08-01), Ayer
patent: 4298002 (1981-11-01), Ronel et al.
patent: 4846793 (1989-07-01), Leonard et al.
patent: 4871094 (1989-10-01), Gall et al.
patent: 4959217 (1990-09-01), Sanders
patent: 4994028 (1991-02-01), Leonard et al.
patent: 5004614 (1991-04-01), Staniforth
patent: 5035891 (1991-07-01), Runkel et al.
patent: 5266325 (1993-11-01), Kuzma
patent: 5273752 (1993-12-01), Ayer
patent: 5292515 (1994-03-01), Moro
patent: 5614223 (1997-03-01), Sipos
patent: 5756127 (1998-05-01), Grisoni
patent: 5817343 (1998-10-01), Burke
patent: 5854382 (1998-12-01), Loomis
patent: 5876761 (1999-03-01), Bodmer et al.
patent: 5894458 (1999-04-01), Takizawa et al.
patent: 6159490 (2000-12-01), Deghenghi
patent: 6337318 (2002-01-01), Trigg et al.
patent: 6361797 (2002-03-01), Kuzma et al.
patent: 2004/0071736 (2004-04-01), Quinn et al.
patent: 2004/0097419 (2004-05-01), Petersen et al.
patent: 2005/0143303 (2005-06-01), Quay et al.
patent: 0246653 (1987-11-01), None
patent: 314206 (1989-05-01), None
patent: 0 384 646 (1993-06-01), None
patent: 821383 (1937-12-01), None
patent: 1 306 541 (1973-02-01), None
patent: WO 98/44964 (1998-10-01), None
patent: WO-02/49573 (2002-06-01), None
patent: WO 02/078597 (2002-10-01), None
patent: WO-2004/071736 (2004-08-01), None
patent: WO 2005/013936 (2005-02-01), None
patent: WO-2005/041873 (2005-05-01), None
patent: WO-2006/099288 (2006-09-01), None
patent: WO-2008/061355 (2008-05-01), None
Schlegel et al., Effective Long-Term Androgen Suppression in Men with Prostate Cancer using A Hydrogel Implant with the GnRH Agonist Histrelin, 2001, Urology 58(4):578-582.
Langer, “Implantable Controlled Release Systems,” Pharmac. Ther. (1983), vol. 21 pp. 35-51.
Gennaro A.R., Remington: the Science and Practice of Pharmacy, 19th Edition, p. 1662.
Lan NaLee, “Volume of Blood in a Human” from http://hypertextbook.com/facts/1998/LanNaLee.shtml, (1998) updated (2001.
Shi et al. (Expert Opin. Drug Deliv. 2005, 2(6), pp. 1039-1058).
Precocious Puberty [online] May 2010 retrieved from: http://www.childrensmemorial.org/depts/endocrinology/precocious-puberty.aspx; 4 pages.
Ostrenski (Gynecology 2001, Lippinocott Williams & Wilkins, p. 12) 2 pages.
Mayoclinic precocious puberty [online] retrieved from http://www.mayoclinic.com/health/precociouspuberty/DS00883 on Jul. 14, 2011; 9 pages.
Burradell, L. B. et al., “Histrelin: A Review of its Pharmacological Properties and Therapeutic Role in Central Precocious Puberty,”Drugs, vol. 45, No. 4, Apr. 1993, pp. 570-588; published by Adis International Limited.
Feuillan, P. P. et al., “Follow-up of children and young adults after GnRH-agonist therapy for central precocious puberty,”J. Endocrinol. Invest., vol. 24, 2001, pp. 734-736; published by Editrice Kurtis.
Berge, et al.,; “Pharmaceutical Salts” J. Pharm. Sci., 1977 66:1-19.
Higuchi, et al.; “Pro-Drugs as Novel Delivery Systems” vol. 14 of the ACS Symposium Series, 1975.
Roche, et al.,; “Bioreversible Carriers in Drug Design” American Pharm. Association and Pergamon Press, 1987.
Schlegel et al., Effective Long-Term Androgen Suppression in Men with Prostate Cancer using A Hydrogel Implant with the GnRH Agonist Histrelin, 2001, Urology 58(4):578-582.
Chertin et al., An implant Releasins the Gonadotropin Hormone-Releasing Hormone Agonist Histrelin Maintains Medical Castration for up to 30 Months in Metastatic Prostate Cancer, 2000, J. Urology 163(3):838-844.
American Peptide Company, Inc., Peptide Catalog 2006-2007, pp. 119, 171, 175, 211, 217, 219, 227, 296, 315, 317 and 329.
Bodmer D., et al: “Factors influencing the release of peptides and proteins from biodegradable parenteral depot systems” Journal of Controlled Release, Elsevier, Amsterdam, NL LNKD- DOI:10.1016/0168-3659(92)90014-I, vol. 21, No. 1-3, Jul. 1, 1992 , pp. 129-137, XP025702099 ISSN: 0168-3659 [retrieved on Jul. 1, 1992].
European Search Report for EP/00904513, completed Mar. 27, 2003.
European Search Report for EP/92300394, completed Sep. 28, 1992.
European Search Report for EP/92300395, dispatched Feb. 27, 2995.
International Search Report PCT/US2009/048475 dated Jun. 1, 2010.
Non-final Office Action for U.S. Appl. No. 11/372,749, mail date Feb. 5, 2008.
Non-final Office Action for U.S. Appl. No. 12/490,971, mail date Sep. 14, 2010.
Non-final Office Action received for U.S. Appl. No. 12/490,971 dated Feb. 2, 2011.
Notice of Allowance for U.S. Appl. No. 12/240,690, mail date Mar., 26, 2010.
Notice of Allowance for U.S. Appl. No. 12/171,999, mail date Mar. 22, 2010.
Notice of Allowance received for U.S. Appl. No. 12/490,979 dated Feb. 4, 2011.
International Preliminary Report on Patentability received for PCT/US2009/048475 dated Jan. 5, 2011.
O'Donnell, et al “Therapeutic Potential of a Long Acting Somatostatin Analogue in Gastrointestinal Diseases” GUT, 1989, vol. 30, pp. 1165-1172.
Office Action for U.S. Appl. No. 07/589,957, mail date Oct. 17, 1991.
Prommer, “Established and Potential Therapeutic Applications of Octreotide in Palliative Care”, Support Care Cancer, 2008, vol. 16, pp. 1117-1123.
Remington's Pharmaceutical Sciences, Osol., A. ed., Mack Publishing Co., (1980), 4 pages (cover and table of contents only).
Spitz, et al. “GnRH Superanalog Implants for Prostate Cancer” Proceedings of the 12th International Congress of Endocrinology, 2004, pp. 389-395.
Supplementary European Search Report for EP/06738004, completed Jun. 23, 2010.
Arnold Ernst
Endo Pharmaceuticals Solutions Inc.
Foley & Lardner LLP
Lomprey Jeffrey R.
Villacorta Gilberto M.
LandOfFree
Compositions and methods for treating precocious puberty does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating precocious puberty, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating precocious puberty will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4257558